The annual ISPE Aseptic Conference continues to provide cutting-edge education in aseptic technology. The 2018 ISPE Aseptic Conference, 6 -7 March in Reston, VA, marks 27 years of providing information to ensure safe and reliable product supply while providing patient safety.
I’m very pleased to share that this year’s conference includes a new half-day track on highly potent/toxic aseptic products.
Highly Potent/Toxic Products are a new generation of combined products like ADCs (Antibody Drug Conjugates) or Cell, Immune, or Gene therapies found in Regenerative Medicine. This new generation of products requires more precautions during manufacturing and cleaning operations to protect human operators and prevent cross contamination in shared facilities. In the new Highly Potent/Toxic Aseptic Track, case study presentations will explore unique requirements and challenges related to product processing and industrial hygiene and provide a CMO perspective on manufacturing these products.
As part of the planning committee, I can share with confidence that the 2018 ISPE Aseptic Conference provides content-rich education sessions with thought-provoking dialogue and discussions you will not want to miss.
I am looking forward to attending the Aseptic Conference, as it helps me to expand my network, learn and benchmark from pharmaceutical industry leaders, and get an up-close and personal view of innovations that will shape the industry. Check back often over the next several weeks, as we’ll be sharing more about the 2018 ISPE Aseptic Conference. I look forward to seeing you there.
The 2018 ISPE Aseptic Conference will feature a keynote presentation from Robert Sausville, Director of Case Management, Office of Compliance and Biologics Quality, FDA/ CBER /QCBQ/DCM on "Aseptic Processing Points to Consider: After 30 Years of Pondering." The conference also features a first-time presentation of polling results from ISPE's 2017 Survey on Aging Facilities, a challenge for the majority of owners in this business.
Additional notable highlights include:
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...